ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications

The introduction Caplacizumab in the management of Immune thrombotic thrombocytopenic purpura (iTTP) has raised different questions, considering its cost-efficacy and the optimal immunosuppressive treatment (IST) to associate. A retrospective multicenter collection of 42 first iTTP cases was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Dainese, Cristina, Valeri, Federica, Pizzo, Eleonora, Valpreda, Alessandra, Sivera, Piera, Montaruli, Barbara, Porreca, Annamaria, Massaia, Massimo, Bruno, Benedetto, Borchiellini, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Biomarkers for Evaluating the Risk and Prognosis of Vascular Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490478/
https://www.ncbi.nlm.nih.gov/pubmed/36124377
http://dx.doi.org/10.1177/10760296221125785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490478/
https://www.ncbi.nlm.nih.gov/pubmed/36124377
http://dx.doi.org/10.1177/10760296221125785

Ejemplares similares